BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19176054)

  • 1. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
    Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
    Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4′,6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation.
    Mi C; Ma J; Shi H; Li J; Wang F; Lee JJ; Jin X
    J Pharmacol Sci; 2014; 125(2):193-201. PubMed ID: 25075425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
    J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.